The broader clinical data is encouraging
Beyond 12 months Clinical trials for both Mounjaro and Wegovy show continued weight loss beyond 12 months at therapeutic doses, with average total weight loss of 20 to 22% for tirzepatide 15mg and 14 to 15% for semaglutide 2.4mg at the end of 72-week and 68-week trials respectively
In animal models, BPC 157 demonstrates intriguing biological activity
In the obesity trial, proportions of subjects reporting nausea were 14-60% with retatrutide versus 11% with placebo [3]
2) Growth hormone secretagogues (GHSs), such as growth hormonereleasing peptides (GHRPs) and growth hormonereleasing hormone (GHRH) analogs, are synthetic compounds that stimulate growth hormone (GH) release in humans
If you suspect temperature excursion or have questions about your medication's stability, contact your prescribing provider or compounding pharmacy immediately